Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Saturday. The firm set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Price Performance

Shares of NASDAQ PULM opened at $6.40 on Friday. The stock has a fifty day moving average price of $4.69 and a 200 day moving average price of $2.98. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $8.44. The company has a market cap of $23.37 million, a PE ratio of -2.42 and a beta of 1.54.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.